Literature DB >> 25935779

Conservative management of morbidly adherent placenta: expert review.

Karin A Fox1, Alireza A Shamshirsaz2, Daniela Carusi3, Angeles Alvarez Secord4, Paula Lee4, Ozhan M Turan5, Christopher Huls6, Alfred Abuhamad7, Hyagriv Simhan8, John Barton9, Jason Wright10, Robert Silver11, Michael A Belfort2.   

Abstract

Over the last century, the incidence of placenta accreta, increta, and percreta, collectively referred to as morbidly adherent placenta, has risen dramatically. Planned cesarean hysterectomy at the time of cesarean delivery is the standard recommended treatment in the United States. Recently, interest in conservative management has resurged, especially in Europe. The aims of this review are the following: (1) to provide an overview of methods used for conservative management, (2) to discuss clinical implications for both clinicians and patients, and (3) to identify areas in need of further research.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  accreta; conservative management; increta; percreta

Mesh:

Substances:

Year:  2015        PMID: 25935779     DOI: 10.1016/j.ajog.2015.04.034

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  22 in total

Review 1.  The role of extracellular matrix in normal and pathological pregnancy: Future applications of microphysiological systems in reproductive medicine.

Authors:  Blakely B O'Connor; Benjamin D Pope; Michael M Peters; Carrie Ris-Stalpers; Kevin K Parker
Journal:  Exp Biol Med (Maywood)       Date:  2020-07-08

2.  Assessment of the massive hemorrhage in placenta accreta spectrum with magnetic resonance imaging.

Authors:  Jie Zhang; Han Xu; Yinghui Xin; Chunhua Zhang; Zhiling Liu; Xue Han; Qingwei Liu; Yan Li; Zhaoqin Huang
Journal:  Exp Ther Med       Date:  2020-01-15       Impact factor: 2.447

3.  Conservative and timely treatment in retained products of conception: a case report of placenta accreta ritention.

Authors:  Antonella Guarino; Luisa Di Benedetto; Chiara Assorgi; Alessandra Rocca; Donatella Caserta
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  Prophylactic occlusion balloon placement in internal iliac arteries for the prevention of postpartum haemorrhage due to morbidly adherent placenta: short term outcomes.

Authors:  Salvatore Alessio Angileri; Leto Mailli; Claudio Raspanti; Anna Maria Ierardi; Gianpaolo Carrafiello; Anna-Maria Belli
Journal:  Radiol Med       Date:  2017-05-27       Impact factor: 3.469

Review 5.  Risk of Subsequent Hysterectomy after Expectant Management in the Treatment of Placenta Accreta Spectrum Disorders.

Authors:  Anca Maria Panaitescu; Gheorghe Peltecu; Radu Botezatu; George Iancu; Nicolae Gica
Journal:  Medicina (Kaunas)       Date:  2022-05-19       Impact factor: 2.948

6.  Management of placenta percreta in a Jehovah's Witness patient.

Authors:  Adriana J Wong; Matthew Schlumbrecht; Marilyn Huang
Journal:  BMJ Case Rep       Date:  2018-06-11

7.  Buttock Necrosis after Uterine Artery Embolization for Delayed Hysterectomy in Placenta Percreta.

Authors:  Devin D Smith; Annette Perez-Delboy; William M Burke; Ana I Tergas
Journal:  Case Rep Obstet Gynecol       Date:  2016-12-06

Review 8.  Successful anticoagulant therapy for disseminated intravascular coagulation during conservative management of placenta percreta: a case report and literature review.

Authors:  Shinya Matsuzaki; Kiyoshi Yoshino; Masayuki Endo; Takuji Tomimatsu; Tsuyoshi Takiuchi; Kazuya Mimura; Keiichi Kumasawa; Yutaka Ueda; Tadashi Kimura
Journal:  BMC Pregnancy Childbirth       Date:  2017-12-29       Impact factor: 3.007

9.  The effectiveness of double incision technique in uterus preserving surgery for placenta percreta.

Authors:  Ibrahim Polat; Burak Yücel; Ali Gedikbasi; Halil Aslan; Aysun Fendal
Journal:  BMC Pregnancy Childbirth       Date:  2017-04-27       Impact factor: 3.007

Review 10.  Endovascular Interventions for the Morbidly Adherent Placenta.

Authors:  Claire Kaufman; Anthony Tadros
Journal:  J Clin Med       Date:  2018-05-01       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.